ADULT PRESCRIPTION AND SERVICE REQUEST FORM SIMLANDI® (adalimumab-ryvk) injection

teva | Shared Solutions® for Biosimilars

☐ Medicare ☐ Medicaid ☐ VA ☐ Other government-sponsored plan

If signed by someone other than the patient, describe legal authority to do so:

ENROLLMENT FORM

PLEASE FAX COMPLETED FORM TO 866-676-4073 FOR OUESTIONS, CALL 888-587-3263

Rx Group #:

Rx PCN #:

	_	-	1	-
_		$\boldsymbol{\sim}$	rı	
_		_		

Requested Services:

Patient Name (First MI Last):			
DOB (mm/dd/yyyy):	Phone:		
Address:			
City:	State: ZIP:		,
Contact Name (if other than patient):	Contact Phone:		
Preferred Language: ☐ English ☐ Spanish ☐ Other	☐ Spanish ☐ Other ☐ Gender: ☐ Male ☐ Female ☐ Unspecified		co

Rx Insurance Name:

Rx ID #:

Rx BIN #:

☐ Benefits Verification ☐ Prior Authorization Support ☐ Commercial Copay Program ☐ Appeals Support

ጓ	PATIENT OR PERSONAL REPRESENTATIVE SIGNATURE(S)

Group #:

PATIENT AUTHORIZATION

Medical Insurance Name:

Medical Insurance ID #:

Cardholder Name:

I authorize my healthcare providers, pharmacies, and health plan(s) to disclose my personal health information on this form as well as information related to my medical condition, treatment, care management, prescriptions, and health insurance to Teva Pharmaceuticals, Inc. and its affiliates, contractors and agents, including their third party patient support program service provider (collectively "Teva") for the purposes described below.

PLEASE INCLUDE COPIES OF INSURANCE CARDS, FRONT AND BACK

I understand that the purpose of this Authorization is to provide me with access to services related to my prescribed medication and/or medical condition ("Program"), including (i) enrollment in the Program; (ii) conducting benefits investigation and coordinating my insurance coverage, which may include allowing a Teva field based representative to access my information and engage with my healthcare provider directly, if necessary; (iii) if needed, determining my eligibility for and coordinating financial assistance; (iv) coordinating prescription fulfillment and product replacement; (v) providing nursing support; (vi) facilitating quality and adverse event reporting activities; (vii) conducting data analytics, market research, and Program related business activities; (viii) contacting me by direct mail or by electronic or telephonic means to the contact information on this form or to any future contact information provided by me or on my behalf in connection with carrying out the Program services, including adherence related communications, reminders, and support, for which the third party service provider may receive financial remuneration from the manufacturer of your medication

I understand that I may cancel this Authorization at any time, by writing to Teva, Attn: Authorizations, P.O. Box 7613, Overland Park, KS 66207, but my cancellation will not apply to any information already disclosed pursuant to this Authorization. This Authorization will remain in effect until the Program ends. I understand that once my information is disclosed, it may be subject to redisclosure by the recipients and no longer protected by federal privacy law. I understand that my treatment, payment for treatment, insurance enrollment, or eligibility for insurance benefits will not be directly affected if I do not sign this Authorization. However, if I do not sign this Authorization, I may not be able to receive Program services. I am also entitled to a copy of this signed Authorization.

Patient Signature: X

CANNOT process form without signature and date



cannot process form without this section completed

ADULT PRESCRIPTION AND SERVICE REQUEST FORM SIMLANDI® (adalimumab-ryvk) injection

teva | Shared Solutions® for Biosimilars

ENROLLMENT FORM

PLEASE FAX COMPLETED FORM TO 866-676-4073
FOR QUESTIONS, CALL 888-587-3263

Healthcare Professional

1 PHYSICIAN INFORMATION (PHYSICIAN TO COMPLETE SECTIONS 1-3)							
Physician Nam	ne:		NPI#:				
Address:			Group Tax ID #:				
City:		State:		ZIP:			
Office Contact	t Name:	Contact Title:	Contact Title:				
Contact Phone	2:	Contact Fax:					
2 PRESCRIPTION INFORMATION							
Patient Name	(First MI Last):	DOB (mm/dd/yyyy):					
□ New □ Switch □ Restart DIAGNOSIS □ Rheumatoid Arthritis (RA) □ Psoriatic Arthritis (PsA) □ Ankylosing Spondylitis (AS) □ Crohn's Disease (CD) □ Ulcerative Colitis (UC) □ Plaque Psoriasis (Ps) □ Uveitis □ Hidradenitis Suppurativa (HS)							
PHARMACY P	RESCRIPTION Please select the medication, and cor	nplete and sign th	e corresponding pharmacy	prescription			
Patient's preferred Specialty Pharmacy*Number of refillsDo not send to Specialty Pharmacy *Prescription will be triaged to preferred pharmacy unless otherwise dictated by insurance mandate and/or patient preference.							
	RHEUMATOID ARTHRITIS	CRO	OHN'S DISEASE or ULCERA	TIVE COLITIS			
SIMLANDI Autoinjector 40 mg/0.4 mL	Select Recommended Dose 40 mg SC every other week 40 mg SC every week¹ 80 mg SC every other week† For patients not receiving methotrexate	SIMLANDI Autoinjector 40 mg/0.4 mL	Select Recommended D Initial dose: 160 mg SC on Day 1 (given in one day or split over two consecutive days), followed by 80 mg SC on Day 15	ose(s) Maintenance dose: 40 mg SC every other week starting on Day 29			
PLAQUE PSORIASIS or UVEITIS							
	Select Recomi	mended Dose(s)					
SIMLANDI Autoinjector 40 mg/0.4 mL	□ Initial dose: 80 mg SC	☐ Maintenance initial 80 mg	e dose: 40 mg SC every other we SC dose	ek starting one week after			
PSORIATIC ARTHRITIS or ANKYLOSING SPONDYLITIS HIDRADENITIS SUPPURATIVA							
Select Recommended Dose			Select Recommended D	` '			
SIMLANDI Autoinjector 40 mg/0.4 mL	☐ 40 mg SC every other week	SIMLANDI Autoinjector 40 mg/0.4 mL	☐ Initial dose:160 mg SC on Day 1 (given in one day or split over two consecutive days), followed by 80 mg SC on Day 15	Maintenance dose: ☐ 40 mg SC every week starting on Day 29 ☐ 80 mg SC every other week starting on Day 29			

PRESCRIBER SIGNATURE

After discussing the Program for my prescribed medication and/or medical condition (including its agents, service providers, and dispensing pharmacies) with the patient, the patient has elected to participate in the Program. I authorize the release of medical and/or other patient information relating to therapy to this Program, Teva Pharmaceuticals, Inc., its affiliates and its designated agents and service providers (collectively, "Teva"), to use and disclose as needed for fulfillment of the prescription related to this Program, and furnish any information in this form to the insurer of the above-named patient. I understand that Teva reserves the right to modify or terminate this Program at any time for any reason without any prior notice. I understand that I am under no obligation to prescribe a specific drug and I have not received, nor will I receive any benefit, for prescribing a specific drug. I certify that I have a signed copy on file of my patient's current and completed Patient Authorization so that I may share this patient's health information with Teva.

STAMP SIGNATURE NOT PERMITTED – INK SIGNATURE ONLY. Please attach all prescriptions on Official State Prescription form if mandated by individual state laws

The prescriber is to comply with his/her state-specific prescription requirements such as e-prescribing, state-specific prescription form, or hard copy prescription, etc.

Prescriber Signature: X

Date: X

form without signature and date

CANNOT

